Table 1. Patient characteristics.
Patient no. | Sex | Age at TX | Diagnosis | Donor | Source | Conditioning | GVHD prophylaxis | PCR-positive results in stool, first and last day | highest PCR-positive results in stool, copies/g | PCR-positive results in blood, first and last day | HAdV strain | Antiviral treatment | CD3+ >50/µl post TX, day | Detection of ADV-specific T cells during ADV-clearance, yes/no | Detection of ADV-specific T cells after ADV-clearance, yes/no | Status at month 6 post TX concerning ADV infection |
1 | w | 19 | T-ALL | FD, haplo, m T cell depletion | PBSC | Flu/VP16/OKT3 | mmf | day 102–272 | 5×10E7 | day 109–110, 6×10E5 | C | Cidofovir | between day 34–41 | no | yes | died after Heart TX, no ADV infection |
2 | m | 2 | M Kostmann | MUD, m | BM | Flu/Thio/Mel/ATG | CyA, mmf | day 21–260 | 2×10E7 | not positive | C | Cidofovir | between day 14–21 | no | yes | still alive, no ADV infection |
3 | w | 3 | MHC II Deficiency | MFD, f | BM | Flu/Thio/Mel/ATG | CyA, mmf | day –15–75 | 1×10E10 | day 13–27, 1×10E4 | C | Cidofovir + Ribavirin | between day 13–20 | no | yes | still alive, no ADV infection |
4 | w | 8 | NBL Rez. | FD, haplo, m T cell depletion | PBSC | Flu/Thio/Mel/OKT3 | CyA | day 106–252 | 1×10E6 | not positive | C | none | between day 27–41 | not determined | yes | still alive, no ADV infection |
5 | m | 12 | ALL Rez. | MUD, m | BM + Boost (day154) | TBI/VP16/ATG | CyA, MTX | day 21–181 | 2×10E10 | day 27–49, 1×10E3 | A and C | Cidofovir | between day 28–34 | not determined | yes | still alive, no ADV infection |
6 | m | 5 | Sept Granulomatose | MFD, f | BM | Flu/Thio/Mel/ATG | CyA, mmf | day –11–92 | 2×10E5 | not positive | C | none | between day 13–20 | not determined | yes | still alive, no ADV infection |
7 | m | 7 | NBL IV | FD, haplo, f T cell depletion | PBSC | Flu/Thio/Mel/OKT3 | CyA | day 6–118 | 5×10E7 | not positive | B and C | Cidofovir | between day 34–42 | not determined | yes | still alive, no ADV infection |
8 | w | 3 | Hyper IGE Syndrom | MUD, f | BM | Flu/Thio/Mel/ATG | CyA, mmf | day 5–13 | 1×10E4 | not positive | C | Gancyclovir | between day 13–16 | not determined | yes | still alive, no ADV infection |
9 | m | 5 | Fanconi, MDS | MFD, f | BM | FLU/BU/ATG/Campath | CyA, mmf | day 11–281 | 9×10E6 | not positive | A and C | Ribavirin | between day 14–18 | not determined | yes | still alive, no ADV infection |
10 | m | 6 | C ALL Rez. | MUD, f | BM | TBI/VP16/ATG | day 54–61 | 7×10E3 | not positive | C | none | between day 19–22 | not determined | yes | still alive, no ADV infection |
Patient No. 2 had transient enteritic symptoms attributed to clostridium difficile infection;
Patient No. 10 had transient enteritic symptoms attributed to gut GVHD.
GVHD, graft-versus-host disease; ALL, acute lymphoblastic leukemia; Rel, relapse; Morbus Kostmann, MHC II, major histocompatibility complex class II, NBL rel, Neuroblastoma relapse; Sept, septic granulomatous disease; NBL IV, Neuroblastoma grade IV; IGE, immunoglobulin E; MDS, myelodysplastic syndrome; common ALL, FD, family donor; haplo, haploidentical; MUD, matched unrelated donor; MFD, matched family donor; m, male; f, female; PBSC, peripheral blood stem cells; BM, bone marrow; Flu, fludarabine; VP16, Etoposide; ThioMel, Thiotepa Melphalan ATG, antithymocyte globulin; TBI, total body irradiation; mmf, mycophenolate mofetil; CyA, cyclophosphamide A; PCR, polymerase chain reaction; HAdV, adenovirus.